Aibo Medical Reports 11.5% Revenue Growth in Q1 2026 and Completes Acquisition of Demei Medical

China Visit Network DataEyebright Medical Technology (Beijing) Co., Ltd. released its Q1 2026 report on April 21, 2026. During the reporting period, the company achieved operating revenue of 398 million yuan, representing a year-on-year increase of 11.50%. Net profit attributable to shareholders of the listed company was 89.2768 million yuan, marking a slight year-on-year decrease of 3.55%. Non-recurring net profit was 88.5812 million yuan, increasing by 2.73% year-on-year. Net cash flow from operating activities was 18.7044 million yuan, declining by 75.23% year-on-year, primarily due to extended payment terms for some customers. R&D investment amounted to 25.5066 million yuan, accounting for 6.40% of operating revenue, reflecting a year-on-year decrease of 36.24%, mainly because some high-investment R&D projects have entered their later stages with reduced related expenditures. As of the end of the reporting period, the company’s total assets reached 4.765 billion yuan, growing by 22.56% compared to the end of the previous year. Equity attributable to shareholders of the listed company stood at 2.864 billion yuan. The company's core operating data remained stable. Additionally, Eyebright Medical completed the equity acquisition of Delta Medical Technology (Chongqing) Co., Ltd. by the end of March 2026, including equity transfer registration and consideration payment. The assets and liabilities of Delta Medical have been incorporated into the company’s consolidated financial statements.